<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MAXIDEX- dexamethasone suspension/ drops </strong><br>ALCON LABORATORIES, INC.<br></p></div>
<h1>Maxidex® 0.1%<br>(dexamethasone ophthalmic suspension)<br>Sterile</h1>
<div class="Contents">
<div class="Section">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"><span class="Bold"></span>MAXIDEX® 0.1% (dexamethasone ophthalmic suspension) is an adrenocortical steroid prepared as a sterile topical ophthalmic suspension. The active ingredient is represented by the chemical structure:</p>
<p><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a0aa9dc9-265c-4dd6-9b03-276a47217839&amp;name=Maxidex-02.jpg"></p>
<div class="Section">
<a name="section-2.1"></a><p></p>
<h2>Each mL contains</h2>
<p class="First"><span class="Bold">Active: </span>dexamethasone 0.1%. <span class="Bold">Preservative: </span>benzalkonium chloride 0.01%. <span class="Bold">Vehicle: </span>hypromellose 0.5%. <span class="Bold">Inactives: </span>sodium chloride, dibasic sodium phosphate, polysorbate 80, edetate disodium, citric acid and/or sodium hydroxide (to adjust pH), purified water.</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"><span class="Bold"></span>Dexamethasone suppresses the inflammatory response to a variety of agents and it probably delays or slows healing.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as <span class="product-label-link" type="condition" conceptid="374959" conceptname="Contact blepharoconjunctivitis">allergic conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span>, superficial punctuate <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>, <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span> <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>, <span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">iritis</span>, cyclitis, selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>; corneal injury from chemical, radiation, or <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">thermal burns</span>, or penetration of foreign bodies.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Contraindicated in epithelial herpes simplex (<span class="product-label-link" type="condition" conceptid="373404" conceptname="Ophthalmic herpes simplex">dendritic keratitis</span>), <span class="product-label-link" type="condition" conceptid="140633" conceptname="Vaccinia">vaccinia</span>, <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>, and most other viral diseases of the cornea and conjunctiva; <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> of the eye; fungal disease of ocular structures; and in those persons who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any component of this preparation.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Prolonged use may result in <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">ocular hypertension</span> and/or <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, with damage to the optic nerve, defects in visual acuity and fields of vision, and <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataract</span> formation. Prolonged use may suppress the host response and thus increase the hazard of secondary ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical corticosteroids. In acute purulent conditions of the eye, corticosteroids may mask <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or enhance existing <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. If these products are used for 10 days or longer, intraocular pressure should be routinely monitored even though it may be difficult in children and uncooperative patients.</p>
<p> Employment of corticosteroid medication in the treatment of herpes simplex other than epithelial <span class="product-label-link" type="condition" conceptid="373404" conceptname="Ophthalmic herpes simplex">herpes simplex keratitis</span>, in which it is contraindicated, requires great caution; periodic slit-lamp microscopy is essential.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">FOR TOPICAL OPHTHALMIC USE ONLY. The possibility of persistent <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> of the cornea should be considered after prolonged corticosteroid dosing.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Do not touch dropper tip to any surface, as this may contaminate the contents. The preservative in MAXIDEX® (dexamethasone ophthalmic suspension), benzalkonium chloride, may be absorbed by soft contact lenses. MAXIDEX® (dexamethasone ophthalmic suspension) should not be administered while wearing soft contact lenses.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of MAXIDEX® dexamethasone ophthalmic suspension).</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.4"></a><p></p>
<h2>Pregnancy</h2>
<p class="First"></p>
<div class="Section">
<a name="section-7.4.1"></a><p></p>
<h3>Pregnancy Category C</h3>
<p class="First">Dexamethasone has been shown to be teratogenic in mice and rabbits following topical ophthalmic application in multiples of the therapeutic dose.</p>
<p> In the mouse, corticosteroids produce fetal resorptions and a specific abnormality, <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>. In the rabbit, corticosteroids have produced fetal resorptions and multiple abnormalities involving the head, ears, limbs, palate, etc.</p>
<p> There are no adequate or well-controlled studies in pregnant women. MAXIDEX® (dexamethasone ophthalmic suspension) should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the embryo or fetus. Infants born of mothers who have received substantial doses of corticosteroids during pregnancy should be observed carefully for signs of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">hypoadrenalism</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.5"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when MAXIDEX® (dexamethasone ophthalmic suspension) is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.6"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-7.7"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First"><span class="Bold"></span>No overall differences in safety or effectiveness have been observed between elderly and younger patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span> with optic <span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">nerve damage</span>, visual acuity and field defects; <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> formation; secondary ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> following suppression of host response; and perforation of the globe may occur.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">SHAKE WELL BEFORE USING. One or two drops topically in the conjunctival sac(s). In severe disease, drops may be used hourly, being tapered to discontinuation as the <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> subsides. In mild disease, drops may be used up to four to six times daily.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">MAXIDEX® (dexamethasone ophthalmic suspension) in plastic DROP-TAINER® dispensers:</p>
<p>5 mL <span class="Bold">NDC</span> 0998-0615-05</p>
<p>15 mL <span class="Bold">NDC</span> 0998-0615-15</p>
<p><span class="Bold">STORAGE</span></p>
<p>Store upright at 8°-27°C (46°-80°F).</p>
<p><span class="Bold">Rx Only</span></p>
<p>© 2003 Alcon, Inc.</p>
<p><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a0aa9dc9-265c-4dd6-9b03-276a47217839&amp;name=Maxidex-03.jpg"></p>
<p><span class="Bold">ALCON LABORATORIES, INC.</span><br>
						Fort Worth,  Texas  76134  USA<br>
						Printed in  USA</p>
<p><span class="Bold">340907-0803 </span></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MAXIDEX 		
					</strong><br><span class="contentTableReg">dexamethasone suspension/ drops</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0998-0615</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>dexamethasone</strong> (dexamethasone) </td>
<td class="formItem"></td>
<td class="formItem">1 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>benzalkonium chloride</strong></td>
<td class="formItem">0.1 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hypromellose</strong></td>
<td class="formItem">5 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>dibasic sodium phosphate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polysorbate 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>edetate disodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>citric acid and/or sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0998-0615-04</td>
<td class="formItem">5 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0998-0615-05</td>
<td class="formItem">5 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0998-0615-15</td>
<td class="formItem">15 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:0998-0615-06</td>
<td class="formItem">5 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>ALCON LABORATORIES, INC.</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 8/2006<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>0A997DDF-1AE4-FCF2-044F-CAB4C37032F2</div>
<div>Set id: a0aa9dc9-265c-4dd6-9b03-276a47217839</div>
<div>Version: 1</div>
<div>Effective Time: 20060821</div>
</div>
</div> <div class="DistributorName">ALCON LABORATORIES, INC.</div></p>
</body></html>
